Cholesterol Synthesis

Why This Matters

One of the most common misconceptions in medicine is that cholesterol comes primarily from food. The body synthesizes most of the cholesterol it needs every day. This process, known as the mevalonate pathway, produces not only cholesterol but also numerous molecules essential for normal cellular function. Understanding this pathway explains how statins work and why cholesterol is indispensable to life.

What Is the Mevalonate Pathway?

The mevalonate pathway is a series of enzymatic reactions that converts acetyl-CoA into cholesterol.

Although the liver is the major site of cholesterol production, virtually every nucleated cell possesses the machinery required to synthesize cholesterol. This allows each cell to produce cholesterol locally when needed rather than relying entirely on circulating lipoproteins.

HMG-CoA Reductase: The Rate-Limiting Enzyme

The most important regulatory step in cholesterol synthesis is catalyzed by 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.

This enzyme converts HMG-CoA into mevalonate, the committed and rate-limiting step of the pathway. Because of its central role, HMG-CoA reductase serves as the principal target of statin therapy, covered in Chapter 26.

Regulation of Cholesterol Synthesis

Cholesterol synthesis is governed by a feedback system.

When intracellular cholesterol falls, the cell activates sterol regulatory element-binding proteins (SREBPs), which increase the expression of HMG-CoA reductase and LDL receptors. This coordinated response simultaneously increases cholesterol synthesis and enhances cholesterol uptake from the circulation.

When intracellular cholesterol is abundant, these pathways are suppressed, reducing both synthesis and uptake.

More Than Cholesterol

The mevalonate pathway produces far more than cholesterol.

Several intermediates generated along the pathway are required for protein prenylation, intracellular signaling, mitochondrial function, and the synthesis of coenzyme Q10 (ubiquinone), dolichols, and other biologically important compounds.

These products participate in numerous cellular processes unrelated to cholesterol transport, which is part of why interventions on this pathway are evaluated carefully for effects beyond LDL lowering.

Cholesterol Production Throughout the Body

Although the liver synthesizes the greatest quantity of cholesterol, many tissues depend on local production.

The brain synthesizes nearly all of its own cholesterol because circulating cholesterol does not cross the blood-brain barrier in significant amounts. Steroid-producing organs require cholesterol for hormone synthesis, while rapidly dividing cells continuously produce cholesterol to support membrane formation.

Clinical Relevance

Statins reduce cholesterol synthesis by inhibiting HMG-CoA reductase.

Although inhibition of cholesterol synthesis contributes to their effect, the principal reduction in LDL cholesterol occurs because lower intracellular cholesterol stimulates increased hepatic LDL receptor expression, accelerating removal of ApoB-containing lipoproteins from the circulation.

Clinical Pearls

• The body synthesizes most of its cholesterol.
• HMG-CoA reductase catalyzes the rate-limiting step of cholesterol synthesis.
• SREBPs coordinate cholesterol synthesis and LDL receptor expression.
• The mevalonate pathway produces many essential molecules besides cholesterol.
• Statins lower LDL primarily by increasing hepatic LDL receptor activity.

Common Misconceptions

Misconception: Most cholesterol comes from dietary intake.

Reality: Endogenous synthesis provides the majority of the body's cholesterol requirements.

Misconception: The only purpose of the mevalonate pathway is cholesterol production.

Reality: The pathway generates numerous essential molecules required for normal cellular function.

Misconception: Statins lower cardiovascular risk simply by blocking cholesterol synthesis.

Reality: Their greatest benefit results from the secondary increase in hepatic LDL receptor expression and enhanced clearance of ApoB-containing lipoproteins.

Clinical Bottom Line

The mevalonate pathway is the body's primary mechanism for cholesterol synthesis and produces many molecules essential for life. Its activity is tightly regulated to maintain cholesterol homeostasis, and inhibition of HMG-CoA reductase remains one of the most effective strategies for increasing hepatic LDL receptor activity and lowering ApoB-containing lipoproteins.